Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lacosamide, quantity: 100 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; hyprolose; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; macrogol 400 - lacoress (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lacosamide, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; crospovidone; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 6000; macrogol 400; indigo carmine aluminium lake - lacoress (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lacosamide, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; crospovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; iron oxide black; macrogol 400 - lacoress (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lacosamide, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; colloidal anhydrous silica; crospovidone; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 6000; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - lacoress (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Malta - English - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - levetiracetam - film-coated tablet - levetiracetam 100 mg - antiepileptics

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: magnesium stearate; maize starch; colloidal anhydrous silica; povidone; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 400; indigo carmine aluminium lake - use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - levetiracetam, quantity: 1000 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; maize starch; titanium dioxide; hypromellose; macrogol 6000 - use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; povidone; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Ireland - English - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - levetiracetam - film coated tablet - 250 milligram - other antiepileptics

Ireland - English - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - levetiracetam - film coated tablet - 500 milligram - other antiepileptics